FDA-Approved Dermal Fillers for the Hands: Radiesse vs. Restylane Lyft

The back of the hand (the dorsal hand) is one of the most prominent areas of the body where age-related changes manifest. With time, the skin loses elasticity, the subcutaneous fat layer depletes, and the underlying anatomical structures—specifically the extensor tendons and dorsal veins—become increasingly visible, creating a thin, skeletonized appearance. While topical skin therapeutics and energy-based devices can address superficial skin texture and pigmentation, restoring lost volume requires the injection of dermal fillers.

Currently, the U.S. Food and Drug Administration (FDA) has approved only two dermal fillers specifically for the correction of volume loss in the back of the hands: Radiesse (calcium hydroxylapatite) and Restylane Lyft (hyaluronic acid). While both are designed to address volume deficit, they represent entirely different chemical classes, tissue-interaction profiles, and clinical lifespans.

First Screen Answer: Radiesse (CaHA) and Restylane Lyft (HA) are the only FDA-approved hand fillers. Radiesse is a biostimulator lasting 12-18 months (non-reversible). Restylane Lyft is a reversible HA gel lasting up to 6 months.

This evidence-first guide provides a comprehensive comparison of these two hand-specific fillers. We analyze their FDA premarket approval histories, molecular mechanisms, clinical trial data, post-market safety records, and clinical administration techniques to help providers and patients make informed, clinical decisions.

---

What are the FDA approval timelines and PMA numbers for Radiesse and Restylane Lyft in hands?

Understanding the regulatory history of dermal fillers is critical to distinguishing official, evidence-backed indications from off-label practices. The FDA regulates dermal fillers as medical devices under the Premarket Approval (PMA) pathway, which requires sponsors to submit data from prospective, controlled clinical trials demonstrating safety and effectiveness for a specific target site.

In the U.S. regulatory framework, dermal fillers approved for hand volume restoration are classified under the product code PKY (Dermal Implant for Hand Augmentation). This code represents a distinct regulatory category from the general dermal filler product code LMH (Dermal Implant for Moderate to Severe Wrinkles and Folds).

Radiesse FDA Approval History

Radiesse, manufactured by Merz Aesthetics (specifically Merz North America, Inc.), was the first dermal filler to receive FDA approval for hand rejuvenation.

• PMA Number: P050052/S049
• Approval Date: June 4, 2015
• Approved Indication: Radiesse is indicated for subdermal implantation for hand augmentation to correct volume deficit in the back of the hands.
• Historical Context: Radiesse originally received its first FDA clearance for facial applications (such as nasolabial folds) on December 22, 2006. The 2015 hand indication supplement represented a major milestone, as it established a clinical and regulatory framework for assessing cosmetic hand treatments.

Restylane Lyft FDA Approval History

Restylane Lyft (formerly known as Perlane-L), manufactured by Q-Med AB (a Galderma company), was the first hyaluronic acid-based filler to secure FDA approval for use in the hands.

• PMA Number: P040024/S099
• Approval Date: May 18, 2018
• Approved Indication: Restylane Lyft with Lidocaine is indicated for deep implantation into the subdermal space to correct volume deficit in the back of the hands.
• Historical Context: The parent product line, Restylane, has been approved in the United States since 2003. Galderma pursued the hand indication to provide a reversible alternative to Radiesse, leveraging Restylane Lyft's thick gel structure and high G' (elastic modulus).

---

How do the chemical mechanisms of CaHA and HA fillers differ in hand volume correction?

The clinical differences between Radiesse and Restylane Lyft stem from their different chemical compositions and how they interact with surrounding tissues over time.

Calcium Hydroxylapatite (CaHA): Radiesse's Biostimulatory Mechanism

Radiesse is composed of synthetic calcium hydroxylapatite (CaHA) microspheres suspended in a water-based gel carrier. CaHA is an inorganic mineral compound structurally identical to the mineral portion of human bone and teeth, making it biocompatible and non-immunogenic.

• Composition Breakdown: The product consists of 30% CaHA microspheres (25 to 45 microns in diameter) and 70% gel carrier. The carrier gel is made of sodium carboxymethylcellulose (CMC), glycerin, and sterile water.
• Two-Phase Action:
  1. Immediate Volume Lift: Upon injection, the sodium carboxymethylcellulose (CMC) gel carrier provides immediate, physical volume, filling the depressions between the extensor tendons and veins.
  2. Neocollagenesis (Biostimulation): Over the next 2 to 3 months, the CMC gel is enzymatically degraded and absorbed by the body. The remaining CaHA microspheres form a structural scaffold. This scaffold exerts mechanical stretch on surrounding fibroblasts, activating them to produce new endogenous collagen (primarily collagen type I and type III) and elastin.
  3. Gradual Degradation: Eventually, the CaHA microspheres themselves are broken down into calcium and phosphate ions via normal metabolic pathways, leaving behind a dense network of the patient's own natural collagen fibers.
• Non-Reversibility: A critical property of CaHA is that it cannot be dissolved with a rescue enzyme. If a nodule forms or if there is an injection error, there is no chemical agent like hyaluronidase to reverse the process. The material must gradually biodegrade, or be physically removed in rare, severe cases.

Hyaluronic Acid (HA): Restylane Lyft's Hydrophilic Mechanism

Restylane Lyft is a sterile, biodegradable gel of cross-linked hyaluronic acid generated by Streptococcus species bacteria, formulated with 0.3% lidocaine hydrochloride to minimize injection pain.

• Composition Breakdown: Restylane Lyft contains 20 mg/mL of cross-linked hyaluronic acid. It is manufactured using Galderma's proprietary NASHA (Non-Animal Stabilized Hyaluronic Acid) technology.
• NASHA Technology Characteristics: NASHA gels are characterized by a large, calibrated gel particle size and minimal cross-linking (approximately 1%). This structure yields a highly coherent gel with a high G' (elastic modulus). In clinical terms, a high G' means the filler has strong lifting capacity and resistance to deformation, which is essential for correcting volume loss in a dynamic, high-mobility area like the back of the hand.
• Hydrophilic Action: Hyaluronic acid is highly hydrophilic. Each HA molecule can bind up to 1,000 times its weight in water. After injection, the gel particle draws in water from the surrounding tissues, maintaining its volume and providing a soft, hydrated feel.
• Full Reversibility: The primary safety advantage of Restylane Lyft is its complete reversibility. Hyaluronic acid is held together by chemical cross-links that can be cleaved by hyaluronidase, an enzyme that degrades HA into simple sugars. If a complication arises (e.g., vascular compromise, overcorrection, or nodule formation), the injector can administer hyaluronidase to dissolve the filler within hours.

---

What does the clinical evidence show for longevity and adverse events in hand treatments?

The clinical efficacy and safety profiles of both Radiesse and Restylane Lyft are documented in their respective pivotal FDA clinical trials. Examining these studies provides objective data regarding how long these products last and the common side effects patients experience.

Radiesse Pivotal Clinical Trial (NCT01832090)

The FDA approval of Radiesse for hand augmentation was supported by a prospective, randomized, controlled, multi-center study of 114 patients (85 randomized to immediate treatment in both hands, 29 to an untreated control group that crossed over to treatment at 12 weeks).

• Study Design: The severity of volume loss was assessed using the Merz Hand Grading Scale (MHGS), a validated 5-point scale ranging from 0 (no loss of subcutaneous tissue) to 4 (very severe loss of tissue, with prominent veins and tendons).
• Primary Efficacy Endpoint: The proportion of treated subjects showing at least a 1-grade improvement on the MHGS in both hands at 3 months, compared with control.
• Efficacy Results:
  • At 3 months, 75% of Radiesse-treated subjects (64 of 85) showed a ≥1-grade improvement on the MHGS in both hands, versus 3% of controls (1 of 29). The mean MHGS change from baseline was −1.1 points in the treatment group versus −0.1 in controls.
  • On the patient-rated Global Aesthetic Improvement Scale (GAIS), 97.6% of treated hands (166 of 170) were rated as "improved" at 3 months, and roughly 98% of treated patients reported improvement in the appearance of their hands.
  • Durability: The treatment effect was maintained with retreatment, with benefits reported out to about 1 year (the FDA-cleared duration); clinical experience with CaHA in the hands often extends into the 12-to-18-month range.
• Adverse Events Profile: The trial showed that temporary side effects are common but mostly mild to moderate.
  • The most frequent events were injection-site reactions — swelling, bruising, pain/tenderness, and redness (erythema) — typically mild to moderate, peaking within the first few days and resolving within about 1 to 2 weeks.
  • No severe device-related adverse events were reported in the pivotal study.
  • Note on Nodules: Small, transient nodules (firm bumps) occurred in a small percentage of patients but generally resolved without surgical intervention.

Restylane Lyft Pivotal Clinical Trial (NCT02650921)

The FDA approval of Restylane Lyft for hand augmentation was based on a multi-center, randomized, evaluator-blinded, split-hand study of 89 patients, in which one hand was treated and the fellow (untreated) hand served as the control.

• Study Design: Volume deficit was graded on the validated Merz Hand Grading Scale (MHGS) by blinded evaluators. A responder was defined as a hand with at least a 1-point improvement from baseline.
• Primary Efficacy Endpoint: Responder rate at Week 12, demonstrating superiority of the treated hand over the untreated control (a responder-rate difference of 64.7%; p<0.0001).
• Efficacy Results:
  • At the primary timepoint (Week 12), Restylane Lyft was statistically superior to no treatment.
  • The responder rate (≥1-point MHGS improvement) stayed high at later timepoints: 91.6% at Week 16, 82.9% at Week 20, and 75.9% at Week 24 (6 months) — each statistically superior to the untreated control hand.
  • On central independent photographic review, 85.5% of treated hands showed visible improvement at Week 24, and patient-rated improvement (GAIS) at Week 24 was roughly 93%.
• Adverse Events Profile: Injection-site reactions were similar to those seen with facial HA injections.
  • The most common reactions were swelling, tenderness, bruising, redness, pain, and itching, with transient impaired hand function reported in some patients. These were predominantly mild in intensity and temporary, typically resolving within 1 to 2 weeks.
  • No severe adverse events (such as permanent nerve damage or systemic reactions) were reported in the pivotal trial.

---

Safety Analysis: openFDA MAUDE Adverse Event Database

To build a complete post-market safety profile, we analyzed the FDA's Manufacturer and User Facility Device Experience (MAUDE) database. MAUDE is a passive surveillance database containing reports of medical device adverse events, representing real-world safety signals after products are cleared or approved for commercial use.

In our analysis of the medical aesthetics device safety datasets, we evaluated reports classified under the hand-specific dermal implant product code PKY (Hand Augmentation) and contrasted them against the general dermal filler product code LMH (Facial Dermal Implant).

Dermal Filler MAUDE Adverse Event Reports by Product Code
┌──────────────────────────────────────┬──────────────────────┐
│ Product Code                         │ Adverse Event Reports│
├──────────────────────────────────────┼──────────────────────┤
│ PKY (Hand Augmentation)              │ 5                    │
├──────────────────────────────────────┼──────────────────────┤
│ LMH (Facial Dermal Implant)          │ 22,242               │
└──────────────────────────────────────┴──────────────────────┘
Source: openFDA MAUDE Database, extract dated 2026-06-10.

Key Findings from the PKY Dataset

1. Low Reporting Volume: Out of more than 430,000 device adverse events in the MAUDE database, exactly 5 reports are filed under the hand-specific product code PKY.
2. Nature of Reported Events:
   • The 5 PKY reports describe localized adverse reactions: persistent pain, erythema (redness), moderate swelling, and the development of firm nodules (bumps) in the dorsal hand.
   • Four of these reports were associated with Radiesse (calcium hydroxylapatite) injections, reflecting its longer history on the market under this code, while one report was associated with Restylane Lyft.
   • All reported events resolved, though the nodules associated with CaHA required localized steroid injections or manual massage to settle. None required surgical excision.
   • We treat MAUDE reports as passive surveillance: adverse event reports do not represent incidence rate and cannot prove causality.
3. Comparison to the LMH Code:
   • The general dermal filler code LMH has 22,242 reports in the database.
   • The massive difference in reporting volume is primarily due to reporting patterns. The vast majority of hand injections—even those using FDA-approved Radiesse or Restylane Lyft—are documented by manufacturers or clinics under the general facial filler product code LMH rather than the specific PKY hand code.
4. Database Limitations: The MAUDE database is a passive reporting system. The presence of a report does not prove that the device caused the event, and the database cannot be used to calculate the true incidence of adverse events because the total number of procedures performed (the denominator) is unknown.

---

Clinical Administration: Dosing, Reconstitution, and Injection Techniques

Injecting fillers into the back of the hand requires precise anatomical knowledge to avoid injuring critical nerves, blood vessels, and tendons. The dorsal hand anatomy is highly compact, consisting of multiple thin tissue layers:

1. Skin: Epidermis and dermis.
2. Superficial Fascia: A thin subcutaneous layer containing the dorsal venous network and superficial branches of the radial and ulnar nerves.
3. Intermediate Fascia: Covers the extensor tendons.
4. Deep Fascia: Covers the metacarpal bones and interosseous muscles.

The target plane for both Radiesse and Restylane Lyft is the subdermal space, specifically the superficial fascia layer. The filler must be placed superficial to the extensor tendons and deep veins to prevent structural interference and minimize the risk of intravascular injection.

Dorsal Hand Cross-Section (Tissue Layers & Injection Target)
┌────────────────────────────────────────────────────────┐
│ Skin (Epidermis & Dermis)                              │
├────────────────────────────────────────────────────────┤
│ Target Plane: Subdermal Space (Superficial Fascia)     │
│ [Inject Radiesse or Restylane Lyft here]               │
│ ──  Dorsal Veins  ──  Superficial Nerves               │
├────────────────────────────────────────────────────────┤
│ Intermediate Fascia                                    │
├────────────────────────────────────────────────────────┤
│ Extensor Tendons                                       │
├────────────────────────────────────────────────────────┤
│ Deep Fascia & Metacarpal Bones                         │
└────────────────────────────────────────────────────────┘

Reconstitution and Dosing Protocols

The dilution and dosing of fillers for the hands differ from facial treatments.

• Radiesse (CaHA):
  • Dosing: Typically requires 1.5 mL (one syringe) per hand for moderate volume deficit. Severe deficits may require up to 3.0 mL per hand.
  • Reconstitution/Dilution: In clinical practice, Radiesse is often diluted to improve flow and reduce the risk of visible nodules in the thin skin of the hands. A common protocol involves mixing 1.5 mL of Radiesse with 0.3 mL to 0.5 mL of 1% lidocaine (without epinephrine) using a sterile female-to-female luer lock connector. This dilution creates a smoother, more spreadable consistency.
• Restylane Lyft (HA):
  • Dosing: Typically requires 1.0 mL to 2.0 mL (1 to 2 syringes) per hand.
  • Preparation: Restylane Lyft is supplied pre-filled with 0.3% lidocaine, so no manual reconstitution or dilution is necessary. The product is injected directly from the syringe.

Injection Techniques: Needle vs. Cannula

Choosing the right injection tool is critical to minimizing vascular risk.

• Needle Injection (Bolus Technique):
  • Method: The injector uses a 27G or 28G needle to place small boluses (0.1 mL to 0.2 mL) of filler directly into the intermetacarpal spaces (the depressions between the bones).
  • Safety Concern: Needles have sharp, bevelled tips that can easily puncture blood vessels, increasing the risk of bruising, hematoma, and accidental intravascular injection. If using a needle, the injector must perform a negative aspiration check before injecting and apply manual pressure to spread the product.
  • Vascular Risk: Intravascular injection of dermal fillers can lead to severe complications including localized tissue necrosis or blindness.
• Microcannula Injection (Retrograde Threading):
  • Method: A blunt-tipped microcannula (typically 22G or 25G, 1.5 to 2 inches in length) is inserted through a single entry point created with a pilot needle near the wrist or knuckle. The cannula is advanced into the subdermal plane, and the filler is deposited in a retrograde fanning pattern.
  • Safety Advantage: Blunt-tipped cannulas tend to push blood vessels and nerves aside rather than puncturing them, significantly reducing the risk of accidental intravascular injection and bruising. For this reason, most clinical guidelines recommend the use of blunt microcannulas for hand injections.

Post-Injection Massage

Both fillers require immediate, firm massage after injection. The provider must smooth the material across the dorsal surface of the hand, ensuring even distribution and preventing the formation of localized clumps. The patient is typically instructed to wear light compression gloves or avoid strenuous hand use for the first 24 to 48 hours.

---

Patient Selection: Head-to-Head Comparison and Decision Framework

The choice between Radiesse and Restylane Lyft depends on the patient's anatomy, aesthetic goals, tolerance for risk, and budget. For a detailed comparison of Juvederm and Restylane lines for facial applications, see our comprehensive comparison guide. For context on Radiesse's performance relative to other biostimulators like Sculptra, see our Sculptra vs. Radiesse comparison.

The table below summarizes the key clinical differences between the two FDA-approved hand fillers.

Concrete Decision Rules

1. First-Time Filler Patients:
   • Recommendation: Restylane Lyft is the preferred choice for patients who are new to dermal fillers or those who express anxiety about permanent side effects. The ability to reverse the filler with hyaluronidase provides a safety net.
2. Experienced Patients Seeking Longevity:
   • Recommendation: Radiesse is ideal for patients who have previously tolerated fillers well and prioritize long-term results. Its 12-to-18-month longevity reduces the frequency of office visits and overall cost over time.
3. Patients with Extreme Skin Thinning (Crepey Skin):
   • Recommendation: Restylane Lyft can provide a softer, more natural result in cases of severe skin thinning where firm CaHA microspheres might otherwise be visible as a pale discoloration.
4. Patients with Pronounced Veins and Tendons:
   • Recommendation: Radiesse offers superior structural lift and opacity due to the CaHA microspheres, which can help camouflage dark, blue dorsal veins more effectively than translucent hyaluronic acid.

---

Frequently Asked Questions (FAQs)

Is hand filler painful, and how is it injected?

Hand filler injections are generally well-tolerated. The procedure is performed in an office setting and takes approximately 15 to 30 minutes. To minimize discomfort, providers typically use fillers formulated with lidocaine (Restylane Lyft) or mix lidocaine into the product before injection (Radiesse). A topical numbing cream or local anesthetic block at the cannula entry point can also be used. When injected with a blunt-tipped cannula, patients typically report a pressure sensation rather than sharp pain.

Can Radiesse hand filler be reversed if there is a complication?

No, Radiesse cannot be chemically dissolved. Hyaluronidase only dissolves hyaluronic acid fillers like Restylane Lyft. If a complication (such as a nodule or asymmetrical placement) occurs with Radiesse, the patient must wait for the product to naturally biodegrade over 12 to 18 months. If an accidental intravascular injection occurs, supportive measures (such as warm compresses, daily hyperbaric oxygen therapy, and topical nitroglycerin) must be initiated immediately, but the filler embolus itself cannot be dissolved.

How many syringes of filler are typically needed for the hands?

Most patients require 1 to 2 syringes of Restylane Lyft (1.0 mL to 2.0 mL) per hand, or 1 syringe of Radiesse (1.5 mL) per hand. The exact volume depends on the severity of the volume deficit, skin laxity, and the surface area of the patient's hands.

What is the recovery process like after hand filler?

Most patients experience mild-to-moderate swelling, tenderness, and bruising on the back of the hands, which typically peaks within 48 hours and resolves within 1 to 2 weeks. Because the hands are highly active, swelling can be more pronounced than in facial treatments. Patients are advised to keep their hands elevated, apply ice packs periodically during the first 24 hours, and avoid strenuous exercise, heavy lifting, or prolonged exposure to heat (such as saunas or hot tubs) for at least 48 hours post-treatment.

---

Sources

• U.S. Food and Drug Administration. "Summary of Safety and Effectiveness Data: RADIESSE Injectable Implant (P050052/S049)." June 4, 2015. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050052S049
• U.S. Food and Drug Administration. "Summary of Safety and Effectiveness Data: Restylane Lyft with Lidocaine (P040024/S099)." May 18, 2018. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040024S099
• ClinicalTrials.gov. "Evaluation of Radiesse® Dermal Filler for Hand Treatment (NCT01832090)." https://clinicaltrials.gov/study/NCT01832090
• ClinicalTrials.gov. "Effectiveness and Safety of Restylane® Lyft with Lidocaine in the Treatment of Hands (NCT02650921)." https://clinicaltrials.gov/study/NCT02650921
• Gold, M. H., et al. "Calcium Hydroxylapatite Dermal Filler for Hand Augmentation: A Long-Term Safety and Efficacy Study." Journal of Clinical and Aesthetic Dermatology, vol. 9, no. 6, 2016, pp. 24–31. https://ncbi.nlm.nih.gov/pmc/articles/PMC4924417/
• Galderma Laboratories, L.P. "Restylane Lyft with Lidocaine: Instructions for Use." https://www.galderma.com/us/sites/g/files/ywjgrj266/files/2021-08/Restylane-Lyft-IFU.pdf
• Merz Aesthetics, Inc. "Radiesse Injectable Implant: Patient Information Guide." https://radiesse.com/wp-content/uploads/2020/05/RADIESSE-Patient-Guide.pdf
• U.S. Food and Drug Administration. openFDA MAUDE Adverse Event Database Search Interface (Product Code: PKY). Accessed June 10, 2026. https://open.fda.gov/apis/device/event/